Plasma gelsolin (pGSN) has been shown as downregulated in individuals with active COVID-19 disease as compared to healthy subjects [8,52], and very recently, it has been demonstrated that it can be used in a combination with multiple analytes as a significant predictor of COVID-19 hospitalisation and poor outcomes [53]. This evidence concerns the gene GSN and COVID-19.